Concerns about ARIAD overblown, says RBC Capital RBC Capital believes that key investor concerns about thrombotic arterial events and hypertension linked to ARIAD's Iclusig are overblown. The firm doesn't expect adverse events raised by a study of the drug to significantly affect the drug's launch or an upcoming Phase III study. RBC Capital maintains an Outperform rating on the stock.
News For ARIA From The Last 14 Days
Check below for free stories on ARIA the last two weeks.